AAAAAA

   
Results: 1-14 |
Results: 14
Lamivudin in the treatment of chronic hepatitis B - a retrospective analysis in German centers
Authors: Teuber, G Lohr, HF Kallinowski, B Berg, T Muller, R Zeuzem, S
Citation: G. Teuber et al., Lamivudin in the treatment of chronic hepatitis B - a retrospective analysis in German centers, DEUT MED WO, 126(5), 2001, pp. 97-102
Randomized, placebo-controlled, double-blind trial with interferon-alpha with and without amantadine sulphate in primary interferon-alpha nonresponders with chronic hepatitis C
Authors: Teuber, G Berg, T Naumann, U Raedle, J Brinkmann, S Hopf, U Zeuzem, S
Citation: G. Teuber et al., Randomized, placebo-controlled, double-blind trial with interferon-alpha with and without amantadine sulphate in primary interferon-alpha nonresponders with chronic hepatitis C, J VIRAL HEP, 8(4), 2001, pp. 276-283
Comparison of new faecal antigen test with C-13-urea breath test for detecting Helicobacter pylori infection and monitoring eradication treatment: prospective clinical evaluation
Authors: Braden, B Teuber, G Dietrich, CF Caspary, WF Lembcke, B
Citation: B. Braden et al., Comparison of new faecal antigen test with C-13-urea breath test for detecting Helicobacter pylori infection and monitoring eradication treatment: prospective clinical evaluation, BR MED J, 320(7228), 2000, pp. 148-148
Perihepatic lymph nodes as a marker of antiviral response in patients withchronic hepatitis C infection
Authors: Dietrich, CF Stryjek-Kaminska, D Teuber, G Lee, JH Caspary, WF Zeuzem, S
Citation: Cf. Dietrich et al., Perihepatic lymph nodes as a marker of antiviral response in patients withchronic hepatitis C infection, AM J ROENTG, 174(3), 2000, pp. 699-704
Detection of residual hepatitis C virus RNA by transcription-mediated amplification in patients with complete virologic response according to polymerase chain reaction-based assays
Authors: Sarrazin, C Teuber, G Kokka, R Rabenau, H Zeuzem, S
Citation: C. Sarrazin et al., Detection of residual hepatitis C virus RNA by transcription-mediated amplification in patients with complete virologic response according to polymerase chain reaction-based assays, HEPATOLOGY, 32(4), 2000, pp. 818-823
Randomized, double-blind, placebo-controlled trial of interferon Alfa2a with and without amantadine as initial treatment for chronic hepatitis C
Authors: Zeuzem, S Teuber, G Naumann, U Berg, T Raedle, J Hartmann, S Hopf, U
Citation: S. Zeuzem et al., Randomized, double-blind, placebo-controlled trial of interferon Alfa2a with and without amantadine as initial treatment for chronic hepatitis C, HEPATOLOGY, 32(4), 2000, pp. 835-841
Antiviral effect of human recombinant interleukin-12 in patients infected with hepatitis C virus
Authors: Lee, JH Teuber, G von Wagner, M Roth, WK Zeuzem, S
Citation: Jh. Lee et al., Antiviral effect of human recombinant interleukin-12 in patients infected with hepatitis C virus, J MED VIROL, 60(3), 2000, pp. 264-268
Efficacy of a short-term ribavirin plus interferon alpha combination therapy followed by interferon alpha alone in previously untreated patients withchronic hepatitis C: a randomized multicenter trial
Authors: Berg, T Hoffmann, RM Teuber, G Leifeld, L Lafrenz, M Baumgarten, R Spengler, U Zeuzem, S Pape, GR Hopf, U
Citation: T. Berg et al., Efficacy of a short-term ribavirin plus interferon alpha combination therapy followed by interferon alpha alone in previously untreated patients withchronic hepatitis C: a randomized multicenter trial, LIVER, 20(6), 2000, pp. 427-436
Evaluation of factors controlling glucose tolerance in patients with HCV infection before and after 4 months therapy with interferon-alpha
Authors: Konrad, T Zeuzem, S Vicini, P Toffolo, G Briem, D Lormann, J Herrmann, G Berger, A Kusterer, K Teuber, G Cobelli, C Usadel, KH
Citation: T. Konrad et al., Evaluation of factors controlling glucose tolerance in patients with HCV infection before and after 4 months therapy with interferon-alpha, EUR J CL IN, 30(2), 2000, pp. 111-121
Severity of HCV-induced liver damage alters glucose homeostasis in noncirrhotic patients with chronic HCV infection
Authors: Konrad, T Zeuzem, S Toffolo, G Vicini, P Teuber, G Briem, D Lormann, J Lenz, T Herrmann, G Berger, A Cobelli, C Usadel, KH
Citation: T. Konrad et al., Severity of HCV-induced liver damage alters glucose homeostasis in noncirrhotic patients with chronic HCV infection, DIGESTION, 62(1), 2000, pp. 52-59
Retreatment with interferon-alpha and ribavirin in primary interferon-alpha non-responders with chronic hepatitis C
Authors: Teuber, G Berg, T Hoffmann, RM Leifeld, L Lafrenz, M Spengler, U Pape, GR Hopf, U Zeuzem, S
Citation: G. Teuber et al., Retreatment with interferon-alpha and ribavirin in primary interferon-alpha non-responders with chronic hepatitis C, DIGESTION, 61(2), 2000, pp. 90-97
Interferon-alpha improves glucose tolerance in diabetic and non-diabetic patients with HCV-induced liver disease
Authors: Konrad, T Vicini, P Zeuzem, S Toffolo, G Briem, D Lormann, J Herrmann, G Wittmann, D Lenz, T Kusterer, K Teuber, G Cobelli, C Usadel, KH
Citation: T. Konrad et al., Interferon-alpha improves glucose tolerance in diabetic and non-diabetic patients with HCV-induced liver disease, EXP CL E D, 107(6), 1999, pp. 343-349
Improved correlation between multiple mutations within the NS5A region andvirological response in European patients chronically infected with hepatitis C virus type 1b undergoing combination therapy
Authors: Sarrazin, C Berg, T Lee, JH Teuber, G Dietrich, CF Roth, WK Zeuzem, S
Citation: C. Sarrazin et al., Improved correlation between multiple mutations within the NS5A region andvirological response in European patients chronically infected with hepatitis C virus type 1b undergoing combination therapy, J HEPATOL, 30(6), 1999, pp. 1004-1013
Interferon-antibodies and the breakthrough phenomenon during ribavirin/interferon-alpha combination therapy and interferon-alpha monotherapy of patients with chronic hepatitis C
Authors: Hoffmann, RM Berg, T Teuber, G Prummer, O Leifeld, L Jung, MC Spengler, U Zeuzem, S Hopf, U Pape, GR
Citation: Rm. Hoffmann et al., Interferon-antibodies and the breakthrough phenomenon during ribavirin/interferon-alpha combination therapy and interferon-alpha monotherapy of patients with chronic hepatitis C, Z GASTROENT, 37(8), 1999, pp. 715-723
Risultati: 1-14 |